Citi’s 16th Annual
One-on-one meetings –
Morgan Stanley’s 19th Annual Global Healthcare Conference
One-on-one meetings –
Corporate presentation – On-demand starting on
One-on-one meetings –
During the conferences, Prof.
A webcast of the corporate presentation will be available on the Events Page of AC Immune’s website.
About
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >
SupraAntigen® is a registered trademark of
For further information, please contact:
Media Relations Phone: +41 21 345 91 34 Email: saoyuth.nidh@acimmune.com | Investor Relations Phone: +41 21 345 91 90 Email: yves.kremer@acimmune.com |
LaVoie Health Science Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com | U.S. Investors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com |
Forward-looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source:
2021 GlobeNewswire, Inc., source